Paper Details

  1. Home
  2. Paper Details

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.

Author: BonnetJ, CarterS, CostanziJ J, DabichL, DixonD O, DurieB G, FilesJ C, RivkinS, SalmonS E, StephensR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study compared different chemotherapy regimens for 440 patients with multiple myeloma. The study found that a regimen alternating between VMCP and VBAP was more effective in achieving remission (54% without levamisole and 44% with levamisole) compared to VCP (28% without levamisole and 28% with levamisole). The VMCP-VBAP regimen also resulted in significantly longer survival (48 months without levamisole and 33 months with levamisole) compared to VCP (29 months without levamisole and 26 months with levamisole). The study found that adding levamisole to either regimen did not improve response rates or survival. The study concludes that the VMCP-VBAP regimen is an effective treatment for multiple myeloma, while levamisole does not appear to improve outcomes.
Paper Details　
Original Abstract of the Article :
Four hundred forty previously untreated patients with active multiple myeloma were entered into a randomized trial (Southwest Oncology Group [SWOG] study 7927/28) comparing vincristine, melphalan, Cytoxan (Mead Johnson & Company, Evansville, Ind), and prednisone (VMCP) alternating with vincristine, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1986.4.8.1227

データ提供：米国国立医学図書館（NLM）

Combination Chemotherapy: A Winning Strategy for Multiple Myeloma?

When it comes to multiple myeloma, a type of blood cancer, finding the right treatment can feel like searching for an oasis in the middle of a vast desert. This study, conducted by the Southwest Oncology Group, aimed to investigate the efficacy of different combination chemotherapy regimens for treating this disease. The researchers compared the effectiveness of three different treatment groups: VMCP-VBAP, VCP, and VCP with levamisole. The results were clear and compelling, with patients receiving VMCP-VBAP showing significantly improved survival rates and higher response rates to induction therapy.

Improved Survival Duration with Combination Therapy

The study revealed that patients receiving VMCP-VBAP, with or without levamisole, experienced significantly improved survival duration compared to those receiving VCP. The survival durations for VMCP-VBAP without and with levamisole were 48 and 33 months, respectively, compared to 29 and 26 months for VCP without and with levamisole. These results provide strong evidence supporting the use of VMCP-VBAP as an effective treatment option for patients with multiple myeloma.

A Promising Treatment Approach

The findings of this study demonstrate that combination chemotherapy using VMCP-VBAP can significantly improve survival duration and response rates in patients with multiple myeloma. It's a great reminder that in medicine, sometimes two heads are better than one, especially when it comes to finding effective treatment strategies for complex diseases.

Dr.Camel's Conclusion

This research underscores the importance of combination chemotherapy in treating multiple myeloma. The study reveals that VMCP-VBAP, a combination regimen, significantly improves survival duration and response rates compared to other treatment approaches. These findings have significant implications for the treatment of multiple myeloma and provide a promising direction for future research.

Date :
  1. Date Completed 1986-09-17
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

3525768

DOI: Digital Object Identifier

10.1200/JCO.1986.4.8.1227

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.